跳至主要内容
临床试验/JPRN-UMIN000004921
JPRN-UMIN000004921已完成1 期

Phase I trial of S-1 plus Lapatinib in patients with HER-2 positive metastatic breast cancer - Phase I trial of S-1 plus Lapatinib in patients with HER-2 positive metastatic breast cancer

Tokai University School of Medicine0 个研究点目标入组 6 人开始时间: 2011年1月21日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1) with active double cancer 2) with severe complications (congested heart failure, coronary insufficiency, myocardial infarction, angina pectoris or abnormal cardiac rhythm which need to treat, history of cerebrovascular accident, hemorrhagic gastrointestinal ulceration, uncontrolled diabetes, renal failure, active hepatitis, liver cirrhosis) 3) possible infection associated with clinical symptoms such as fever 4) uncontrolled pleural effusion, pericardial effusion 5) pregnant or nursing women or women who like be pregnant 6) with pulmonary fibrosis or pneumonitis 7) with history of mental disorder or treating it at the moment 8) with history of severe allergy 9) with severe allergy to TS-1 and Lapatinib 10) patients receiving Flucytosine 11) doctor's decision not to be registered to this study

研究者

相似试验